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ABSTRACT
OBJECTIVE: To analyze the distribution of adverse events following immunization (AEFI) 
in pregnant women in the state of Minas Gerais, between 2015 and 2019. 
METHODS: This is an epidemiological, descriptive study conducted with AEFI data from 2015 
to 2019, recorded in the Adverse Events Surveillance Information System, in the state of Minas 
Gerais (MG), Brazil. A total of 670 AEFI were analyzed in pregnant women. The estimates were 
presented in proportions, according to the year of occurrence, health macro-region of Minas 
Gerais and immunobiological administered.
RESULTS: The year in which there were the most records was 2017 (36.8%). Among the 
14 macro-regions, the ones with the lowest and highest number of records were the Vale do 
Jequitinhonha (0.5%) and Center (31.8%), respectively. The vaccines contraindicated during 
pregnancy represented 27.6% of the total notifications. The total of 69.5% of the cases were 
considered immunization errors. In 75.9% of the records, the variable of medical care was 
ignored, and in 73.7% of the cases no information on the evolution was presented. 
CONCLUSION: This study shows the need for continuing education for the multidisciplinary 
team, in order to reduce cases of AEFI and ensure the adequate completion of notifications by 
health professionals.
DESCRIPTORS: Vaccination, adverse effects. Pregnant Women. Epidemiology. Information 
Systems.
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INTRODUCTION
Vaccination is a priority, effective and strategic action of Primary Health Care (PHC)1. 
Immunization programs contribute to improving quality and increasing global life 
expectancy by reducing, controlling or eradicating preventable immunopreventable 
diseases2. The Brazilian Immunization Program (PNI), created in 1973, is recognized 
worldwide for providing free access to vaccination for the entire population and for its 
degree of complexity, since the number of immunobiologicals offered is high, and vaccination 
regimens are diversified3. 
Initially, the main target of PNI were children, and over the years IR contributed to improve 
the average vaccination coverage of children under 1 year of age. Throughout its trajectory 
to this day, the program has undergone several modifications in the vaccination schedule. 
Currently, the PNI covers all age groups and life cycles, such as adolescents, older adults 
and pregnant women4.
In the context of the health of Brazilian pregnant women, the vaccination schedule has been 
improved. Pregnant women are at risk of higher complications due to immunopreventable 
and potentially fatal diseases5, because during the gestational period, women undergo 
changes in the immune and physiological system that can increase susceptibility to 
infectious diseases5,6.
Vaccination during pregnancy is a vital preventive measure in routine obstetric care, 
serving to protect the mother, fetus and baby. Vaccines are administered according to 
specific vaccination schedule, based on a vaccine schedule proven effective for pregnant 
women. In view of the increase in the number of immunobiologicals offered and the complex 
management situation provided by the PNI, the occurrence of adverse events following 
immunization (AEFI) has also increased7.
AEFI are severe, undesirable or unexpected signs or symptoms manifested in the individual 
who has received any type of immunobiological. Such events can be caused by several 
factors related to immunobiological components, the vaccination process or the vaccine 
itself7,8. The AEFI are classified according to their extent — local or systemic — and intensity 
— mild (when there is no need for complementary tests or medical treatment); moderate 
(when there is a need for medical evaluation and complementary examinations or medical 
treatment); and severe (when it triggers hospitalization for at least 24 hours, significant or 
persistent dysfunction or disability, that is, sequelae, which results in a congenital anomaly 
or requires immediate intervention to prevent death9.
In 1991, the World Health Organization (WHO) recommended that surveillance of adverse 
events be established after vaccination. In Brazil, in 2000, the Ministry of Health, through 
the PNI, implemented the Information System for Surveillance of Adverse Events Following 
Immunization (IS-AEFI), with the objective of controlling these events through surveillance, 
notification, monitoring and investigation of the cases that occurred, offering subsidies to 
identify predictors and risk groups9.
A study on the influenza vaccination campaign in Cuba evaluated the occurrences and 
severity of AEFI in pregnant women. Only 0.8% of the research participants had AEFI, and 
most events were classified as mild10. Another study analyzed the registration of AEFI in 
hepatitis B vaccines in pregnant women and their perinatal repercussions in the United 
States between 1990 and 2016. Common AEFI stood out in relation to local reactions; there 
was no record of maternal death and no cases of administration error were recorded11.
Despite international studies10–12, in the Brazilian literature, studies on AEFI are still 
incipient. Considering the importance of these events in decision-making in health services 
and the magnitude of their occurrence among pregnant women, this study aimed to analyze 
the distribution of AEFI in pregnant women in the state of Minas Gerais, between 2015 
and 2019.
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METHODS
This is an epidemiological, descriptive study conducted with data from the PNI Information 
System of the state of Minas Gerais (MG), Brazil, from January 1, 2015 to December 31, 
2019. We analyzed all records of this period related to pregnant women, i.e., 670 AEFI. The 
selection flowchart of the AEFI sample in pregnant women can be observed in Figure 1.
The state of Minas Gerais consists of 853 municipalities, distributed in a territory of 
586,522,122 km2, with a population of 21,168,791 inhabitants in 201913,14. The state was divided 
into 14 health macro-regions, considered as a territorial basis for health care planning 
due to their demographic, socioeconomic, geographic, sanitary, epidemiological, service 
provision and relationships among municipalities. Namely: South; South Central; Center; 
Jequitinhonha; West; East; Southeast; North; Northwest; South East; Northeast; Southern 
Triangle; Northern Triangle; and Vale do Aço.
In this study, we analyzed the cases of AEFI with and without closure occurred in the defined 
period. The following variables were analyzed for the cases of AEFI: year of occurrence of 
the event; macro-region of health of occurrence; administered immunobiological; type of 
event (non-severe, severe, immunization error, immunization error with adverse event); 
medical care (yes, no, ignored); and evolution of the case (cure without sequelae, cure with 
sequelae, under follow-up, is not AEFI, death, others).
AEFI notifications were also analyzed based on the national vaccination schedule 
recommended for pregnant women9, with immunobiologicals divided into recommended 
vaccines during pregnancy, vaccines recommended in special situations during pregnancy 
and vaccines contraindicated during pregnancy. These vaccines are recommended during 
pregnancy: the adult-type acellular triple bacterial – diphtheria, tetanus and pertussis 
– (dTpa); the adult duo – diphtheria and tetanus – (dT); hepatitis B; and influenza. 
They are vaccines recommended in special situations during pregnancy (application is 
AEFI: adverse events following immunization.
Figure 1. Sample selection flowchart.
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made through careful analysis of the health service, which will judge the relevance of 
vaccination): hepatitis A and B; pneumococcal; meningococcal ACWY/C conjugated; 
meningococcal B; and yellow fever. And, finally, they are vaccines contraindicated in 
pregnancy: triple viral (measles, mumps and rubella); human papillomavirus (HPV); 
chickenpox (chickenpox) and dengue.
The yellow fever vaccine is contraindicated for pregnant women, however, in the impossibility 
of postponing vaccination, such as in epidemiological emergencies, outbreaks or epidemics, 
the health service should assess the relevance of vaccination. In the state of Minas Gerais, 
in 2017 and 2018, there were epidemiological outbreaks of yellow fever, and unvaccinated 
pregnant women living in areas with active transmission of the disease received a dose 
of the vaccine (in any gestational period)15. For this reason, this immunobiological was 
considered as recommended in special situations during pregnancy. 
The incidence rate (IR) of adverse events per 100,000 doses applied was also estimated. 
For the estimation of IR, the number of AEFI in pregnant women was considered in the 
numerator and, as denominator, the number of doses administered in pregnant women in 
the period, by health macro-region. The number of doses was obtained on the website of 
the Ministry of Health (pni.datasus.gov.br). In the search, the filter available for age group 
(10 to 49 years) was used, considering only the application in pregnant women.
For data analysis, the Statistical Software for Professional (Stata) program, version 14.0, was 
used. The estimates of the AEFI were presented in proportions (%), with their respective 
confidence intervals (95%CI) according to the year of occurrence, health macro-region and 
immunobiological administered. It is emphasized that the number of immunobiologicals 
administered is different from the number of pregnant women, because a single pregnant 
woman may have received more than one immunobiological in the gestational period. For 
the age of the pregnant women, due to the asymmetry in the evaluation by the Shapiro-Wilk 
test, the data were presented by means of median and interquartile range (IQR).
The research, under the title “Vaccination of pregnant women: evaluation of epidemiological 
and clinical aspects in the city of Belo Horizonte,” was approved by the Ethics Committee of 
the Universidade Federal de Minas Gerais, under the protocol CAAE 53843716.0.0000.5149.
RESULTS
From 2015 to 2019, 17,355 AEFI were registered in the state of Minas Gerais; among them, 
670 (3.8%) occurred in pregnant women. The median age of pregnant women who presented 
such events was 28.18 years (IQR: 22.56–33.18). Regarding self-reported skin color, 42.7% of 
the notifications did not bring this information. Among the 384 (57.3%) pregnant women 
who had self-reported skin color, 54.9% were yellow/brown, 34.4% white, and 10.7% black. 
During the period from 2015 to 2016, the number of cases of AEFI in pregnant women 
fluctuated from 7.4% (95%CI: 5.6%–9.7%) (50 cases) in 2016, at 36.8% (95%CI: 33.2%–40.5%) 
(247 cases) in 2017 (Figure 2). 
The data presented in Table 1 show the AEFI by the health macro-regions. The Center 
macro-region, with the highest number of pregnant women in the state from 2015 to 2019 
(32.9% of the total), recorded the highest proportion (31.8%) AEFI. The macro-region with 
the lowest proportion was Jequitinhonha, with 0.5%.
The incidence rate of AEFI for pregnant women, by health macro-regions, can also be 
observed in Table 1. The macro-region with the highest rate of adverse events after 
vaccination was that of Vale do Aço, where 116 EAFI were reported, an incidence rate of 
258.4 cases per 100,000 doses administered in pregnant women. The macro-region with 
the lowest incidence rate was the Jequitinhonha macro-region, with 22.6 AEFI per 100,000 
doses applied.
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Data on administered immunobiologicals can be seen in Table 2. We found that the highest 
proportion (39.9%) recommended vaccines during pregnancy. However, 27.7% of the events 
related to vaccines contraindicated in the gestational period. The immunobiological with 
the highest proportion of AEFI (31.9%) in pregnant women it was the yellow fever vaccine, 
followed by the triple viral (23.6%), contraindicated during pregnancy. 
Table 1. Incidence rate of adverse event following immunization in pregnant women per 100,000 doses 






%b of the total 
population of 






%b of total 
AEFIf
Center 320,536 32.9 293,977 213 72.5 31.8
South-Central 32,952 3.4 25,937 9 34.7 1.3
Jequitinhonha 18,886 1.9 13,284 3 22.6 0.5
East 32,641 3.3 27,427 8 29.2 1.2
South East 38,132 3.9 25,902 20 77.2 3.0
Northeast 38,973 4.0 30,195 9 29.8 1.3
Northwest 32,687 3.4 26,149 8 30.6 1.2
North 83,558 8.6 75,950 29 38.2 4.3
West 54,872 5.6 46,413 32 68.9 4.8
Southeast 63,465 6.5 70,176 24 34.2 3.6
South 121,403 12.5 95,528 91 95.3 13.6
Northern Triangle 61,911 6.3 64,937 61 93.9 9.1
Southern Triangle 36,556 3.7 30,299 47 155.1 7.0
Vale do Aço 38,495 3.9 44,896 116 258.4 17.3
Total 975,067 100.00 871,070 670 76.9 100.00
%: relative frequency; a population of pregnant women from 2015 to 2019; b relative frequency; c the number 
of doses was obtained by the Website of the Ministry of Health (pni.datasus.gov.br) and considered only the 
application in pregnant women; d sample number; e IR: incidence rate of adverse event following immunization in 
pregnant women per 100,000 doses applied; f AEFI:  adverse events following immunization .
Figure 2. Adverse events following immunization in pregnant women (%) and 95%CI, second year of 
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Regarding the vaccines recommended for pregnant women, we observed that the acellular 
bacterial triple (dTpa) was the one that presented the most AEFI (37.5%), followed by the adult 
duo (dT), with 28.1%. Among the immunobiologicals recommended in special situations, 
the yellow fever vaccine accounted for 98.4% of all AEFI in this category. As for vaccines 
Table 2. An adverse event following immunization in pregnant women, according to the 
recommendation of the Ministry of Health for the gestational and immunobiological period (Minas 
Gerais, Brazil, 2015 to 2019).
Immunobiologicals n (%)a n (%)b
Violence during pregnancy 317 (39.9) 317(100)
Adult duo 89 (11.2) 89 (28.1)
Influenza 43 (5.4) 43 (13.6)
Hepatitis B 66 (8.3) 66 (20.8)
Acellular bacterial triple (adult) — 
dTpa
119 (15.0) 119 (37.5)
Recommended in special situations 257 (32.4) 257 (100)
Yellow fever 253 (31.9) 253 (98.4)
Meningococcal conjugated C 2 (0.3) 2 (0.8)
Rabies in Vero cell culture 2 (0.3) 2 (0.8)
Contraindicated 220 (27.7) 220 (100)
DTP/HB/Hib 6 (0.8) 6 (2.7)
Quadrivalent HPV 13 (1.6) 13 (5.9)
Tetra viral 1 (0.1) 1 (0.5)
Triple bacterial DTP 13 (1.6) 13 (5.9)
Triple viral 187 (23.6) 187 (85.0)
Total 794 (100)
%: relative frequency; a % estimated for all immunobiologicals applied; b % estimated in relation to the indication 
of administration.
Table 3. Characteristics of adverse events following immunization among pregnant women, second 




2015 2016 2017 2018 2019
n (%) n (%) n (%) n (%) n (%) n (%)
Immunization error 30 (39.9) 25 (50.0) 199 (80.6) 90 (70.9) 122 (72.2) 466 (69.5)
Immunization error with 
adverse event
2 (2.6) 3 (6.0) 5 (2.0) 4 (3.2) 4 (2.4) 18 (2.7)
Severe 1 (1.3) 2 (4.0) 3 (1.2) - - 6 (0.9)
non-severe 44 (57.2) 20 (40.0) 40 (16.2) 33 (25.9) 43 (25.4) 180 (26.9)
Medical care
Ignored 34 (44.2) 27 (54.0) 210 (85.0) 97 (76.4) 141 (83.4) 509 (76.0)
No 19 (24.7) 9 (18.0) 14 (5.7) 11 (8.7) 10 (5.9) 63 (9.4)
Yes 24 (31.1) 14 (28.0) 23 (9.3) 19 (14.9) 18 (10.7) 98 (14.6)
Evolution of the case
Healing with sequelae - - 1 (0.4) 2 (1.6) - 3 (0.4)
Healing without 
sequelae
38 (49.4) 15 (30.0) 23 (9.3) 16 (12.6) 24 (14.2) 116 (17.3)
Under follow-up 8 (10.4) 7 (14.0) 14 (5.7) 13 (10.2) 4 (2.4) 46 (6.9)
It is not AEFI 1 (1.3) 1 (2.0) 4 (1.6) 4 (3.2) - 10 (1.5)
Lost to follow-up - - - - 1 (0.6) 1 (0.2)
No information 30 (38.9) 27 (54.0) 205 (83.0) 92 (72.4) 140 (82.8) 494 (73.7)
%: relative frequency; AEFI: adverse event following immunization.
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contraindicated during pregnancy, the triple viral vaccine presented 85% of the events in 
this category (Table 2).
Considering the characteristics of the AEFI, we observed that 69.5% of the cases were 
classified as immunization error (Table 4). There was medical care in 14.6% of the reported 
cases; however, in 76% of the AEFI records, the completion of this variable was ignored. 
Of the total of 670 AEFI, 17.3% had cure without sequelae, and the prevalence of records 
without information on the evolution of the case was 73.7% (Table 3).
Finally, among the three pregnant women (0.4%) who had a cure with some type of sequelae, 
we observed that the median age was 33 years (IQR: 24–57). Regarding the immunobiological 
administered, each pregnant woman received a distinct vaccine: triple viral vaccine, trivalent 
influenza and dTpa. Two pregnant women required medical attention. She was hospitalized 
for 2 to 3 days, and one of them, who had received the triple viral, had an abortion.
DISCUSSION
The results of this study showed that the distribution of AEFI in pregnant women in the 
state of Minas Gerais occurred without a determined trend between the years considered, 
with a higher incidence in 2017. The macro-region with the highest percentage of AEFI 
notification was that of the Center, and the macro-region with the highest incidence rate 
was the Vale do Aço. The vaccines with the highest proportion of AEFI registration were 
those not recommended in the national immunization calendar, with yellow fever and 
triple viral being the largest responsible for increasing this number. Immunization error 
was the most prevalent type of event in the population, and 73.7% of the cases did not have 
the evolution of the case reported.
Among the years studied, the ones with the lowest incidence of notifications were those of 
2015 and 2016, with great disparity in relation to the others. The still recent support to the 
Online Module of The IS-AEFI, implemented in 2014, may have influenced the low amount 
of completion of the records. Despite reducing the inconsistencies presented by the offline 
mode, the change requires adaptation of the vaccinators9.
Regarding the number and incidence rate of AEFI in macro-regions, we can infer that 
there is influence of variation in the structure and prenatal care of primary care between 
localities, as observed in other studies16. Thus, factors closely linked to the occurrence and 
notification of AEFI can be highlighted, such as availability of materials, work process and 
provision of guidance to pregnant women and companions16. Concomitantly, other factors 
may be related to this variation, such as low adhering to the recording of these events, lack 
of information on the importance of notifying them and lack of adequate training of health 
professionals to perform notifications8.
Regarding the type of immunobiological, the yellow fever vaccine was the main responsible 
for AEFI: 31.78% of cases. In 2017, as already mentioned, there was an outbreak of the disease 
in Minas Gerais, and therefore the Ministry of Health launched new recommendations for 
vaccination – which led to the increase in vaccinated pregnant women9,17. Normally, live 
virus vaccines are not recommended during pregnancy, only in special cases, when the risk 
of illness overlaps the theoretical vaccination risk9,18.
The second immunobiological with the highest proportion of notification was the triple 
viral, contraindicated during pregnancy. The application may have occurred due to the fact 
that the woman is not aware of the pregnancy at the time. It is known that this vaccine is 
indicated in adulthood if the individual has not been immunized in childhood and is an 
important recommendation for women who wish to become pregnant. In this sense, the 
high rate of AEFI may be related to a large number of applications of childbearing age, unlike 
tetra viral vaccines and HPV, which are also contraindicated9,19. The latter are not offered by 
the Unified Health System (SUS) in adulthood, although the high pregnancy rates among 
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Brazilian adolescents should be highlighted: 68.4 per 1,000 adolescents, above the global 
average (46 per 1,000) and Latin America (65.5 per 1,000)20. DTP/HB/Hib (pentavalent) and 
triple bacterial vaccines are recommended exclusively in childhood7,9.
Regarding the type of adverse event, most cases were classified as non-severe, evolving to 
cure without sequelae or greater harm to patients. The data confirm previous studies, which 
show that the benefits of the prevention of diseases of the fetus through vaccines outweigh 
the risks of possible adverse effects11,17. In addition, a Portuguese study confirmed there were 
no indications of specific events associated with the application of vaccines contraindicated 
during pregnancy. However, studies such as this are still limited and cannot give safety to 
the administration of these vaccines21.
Immunization errors accounted for 69.55% of the AEFI recorded, confirming that such 
errors are the major responsible for AEFI22. These can be considered as any preventable 
event, resulting from failures in the preparation, handling, storage or administration 
of immunobiologicals, in order to reduce or cancel the expected vaccine effect22,23. 
Immunization errors are classified as: error in production (failure to comply with good 
manufacturing practices that can lead to a deviation of quality, such as power changes 
and increased reatogenicity); error in the cold network (vaccine transported or stored 
incorrectly); handling error; and error in administration (non-sterile injection, reconstitution 
error, injection at the incorrect site, contraindication ignored, vaccine out of date), which 
occur due to non-compliance with standards and techniques, which may result in an 
adverse event7,23.
In the high proportion of immunization errors, the work overload of vaccinators can 
have great influence, the devaluation reported by professionals24 and, it is assumed, the 
fact that the woman or professional is not aware of the ongoing pregnancy at the time 
of immunobiological administration. Therefore, the need for continuing education is 
emphasized, in order to update the knowledge of the multidisciplinary team about the 
vaccination schedule for pregnant women recommended by the PNI. This resource is 
necessary in view of the large number of vaccines offered by SUS and the constant updating 
of the national vaccination calendar9.
Also as a result of this study, it is noteworthy that more than half of the notified events 
were closed without information, which indicates failures in filling out notifications. These 
gaps make it difficult to verify the interference of other factors related to AEFI in pregnant 
women. Greater supervision and monitoring of professionals who fill out the notification 
in the IS-AEFI could improve the quality of the database25.
Like any epidemiological study, ours has some limitations. The research was developed 
based on data from secondary banks, limited to specific information. Moreover, we point 
out that some forms were not filled out properly. It is also noteworthy the non-inclusion of 
AEFI notifications made in the Notification System in Sanitary Surveillance (NOTIVISA), 
used by private vaccination services.
CONCLUSION
Although most of the cases registered are not severe, the discussion about such records 
is important to adapt the conduct of multidisciplinary team professionals regarding risk 
assessment in the immunization process of pregnant women. Thus, professionals can act 
more safely, also transmitting it to pregnant women, babies and family members. 
Another important aspect concerns the need to intensify continuing education for health 
professionals, especially in order to improve knowledge about the vaccination schedule 
of pregnant women and so that the possibility of pregnancy is always investigated before 
the administration of the vaccine. In addition, from the greater use of AEFI records, it is 
possible to broaden the understanding of pregnant women about the need for vaccination 
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and about possible adverse events, as well as sensitize professionals to greater attention 
to the adequate and complete filling of the records and greater commitment to notify the 
adverse event in the IS-AEFI, contributing to patient safety. 
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